Effect of Different Antitumor Regimens on Incidence and Severity of Corona Virus Disease 2019 Pneumonia in Lung Cancer Patients : A Single-center Retrospective Study
BACKGROUND: Studies have shown that the incidence and severity of corona virus disease 2019 (COVID-19) in patients with lung cancer are higher than those in healthy people. At present, the main anti-tumor treatments for lung cancer include surgery, immunotherapy, chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. While the effects of different anti-tumor treatments on the occurrence and severity of COVID-19 pneumonia are not uniform. Therefore, we aimed to describe clinical characteristics and antitumor therapy of patients with lung cancer and COVID-19 pneumonia, and examined risk factors for severity in this population.
METHODS: From December 1, 2022 to February 15, 2023, a retrospective study was conducted in 217 patients diagnosed with COVID-19 and pathologically confirmed lung cancer in the Jinling Hospital. We collected data about patients' clinical features, antitumor treatment regimen within 6 months, and the diagnosis and treatment of COVID-19. Risk factors for occurrence and severity of COVID-19 pneumonia were identified by univariable and multivariable Logistic regression models.
RESULTS: (1) Among the 217 patients included, 51 (23.5%) developed COVID-19 pneumonia, of which 42 (82.4%) were classified as medium and 9 (17.6%) were classified as severe; (2) Univariate and multivariate analysis revealed overweight (OR=2.405, 95%CI: 1.095-5.286) and intrapulmonary focal radiotherapy (OR=2.977, 95%CI: 1.071-8.274) are risk factors for increasing occurrence of COVID-19 pneumonia, while other therapies are not; (3) Chronic obstructive pulmonary disease (COPD) history (OR=7.600, 95%CI: 1.430-40.387) was more likely to develop severe pneumonia and anti-tumor therapies such as intrapulmonary focal radiotherapy, chemotherapy, targeted therapy and immunotherapy did not increase severity.
CONCLUSIONS: Intrapulmonary focal radiation therapy within 6 months increased the incidence of COVID-19 pneumonia, but did not increase the severity. However, there was no safety concern for chemotherapy, targeted therapy, surgery and immunotherapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Zhongguo fei ai za zhi = Chinese journal of lung cancer - 26(2023), 6 vom: 20. Juni, Seite 429-438 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Lu, Wanjun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitumor treatment |
|---|
| Anmerkungen: |
Date Completed 28.07.2023 Date Revised 28.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3779/j.issn.1009-3419.2023.102.20 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359882935 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359882935 | ||
| 003 | DE-627 | ||
| 005 | 20231226081826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3779/j.issn.1009-3419.2023.102.20 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359882935 | ||
| 035 | |a (NLM)37488080 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Lu, Wanjun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of Different Antitumor Regimens on Incidence and Severity of Corona Virus Disease 2019 Pneumonia in Lung Cancer Patients |b A Single-center Retrospective Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2023 | ||
| 500 | |a Date Revised 28.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Studies have shown that the incidence and severity of corona virus disease 2019 (COVID-19) in patients with lung cancer are higher than those in healthy people. At present, the main anti-tumor treatments for lung cancer include surgery, immunotherapy, chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. While the effects of different anti-tumor treatments on the occurrence and severity of COVID-19 pneumonia are not uniform. Therefore, we aimed to describe clinical characteristics and antitumor therapy of patients with lung cancer and COVID-19 pneumonia, and examined risk factors for severity in this population | ||
| 520 | |a METHODS: From December 1, 2022 to February 15, 2023, a retrospective study was conducted in 217 patients diagnosed with COVID-19 and pathologically confirmed lung cancer in the Jinling Hospital. We collected data about patients' clinical features, antitumor treatment regimen within 6 months, and the diagnosis and treatment of COVID-19. Risk factors for occurrence and severity of COVID-19 pneumonia were identified by univariable and multivariable Logistic regression models | ||
| 520 | |a RESULTS: (1) Among the 217 patients included, 51 (23.5%) developed COVID-19 pneumonia, of which 42 (82.4%) were classified as medium and 9 (17.6%) were classified as severe; (2) Univariate and multivariate analysis revealed overweight (OR=2.405, 95%CI: 1.095-5.286) and intrapulmonary focal radiotherapy (OR=2.977, 95%CI: 1.071-8.274) are risk factors for increasing occurrence of COVID-19 pneumonia, while other therapies are not; (3) Chronic obstructive pulmonary disease (COPD) history (OR=7.600, 95%CI: 1.430-40.387) was more likely to develop severe pneumonia and anti-tumor therapies such as intrapulmonary focal radiotherapy, chemotherapy, targeted therapy and immunotherapy did not increase severity | ||
| 520 | |a CONCLUSIONS: Intrapulmonary focal radiation therapy within 6 months increased the incidence of COVID-19 pneumonia, but did not increase the severity. However, there was no safety concern for chemotherapy, targeted therapy, surgery and immunotherapy | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antitumor treatment | |
| 650 | 4 | |a Corona virus disease 2019 | |
| 650 | 4 | |a Lung neoplasms | |
| 700 | 1 | |a Lv, Jiawen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Yanwen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jiayan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Guannan |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Xiaoling |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Huijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yajuan |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Hedong |e verfasserin |4 aut | |
| 700 | 1 | |a Lv, Tangfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Ping |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhongguo fei ai za zhi = Chinese journal of lung cancer |d 1998 |g 26(2023), 6 vom: 20. Juni, Seite 429-438 |w (DE-627)NLM199966222 |x 1999-6187 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:6 |g day:20 |g month:06 |g pages:429-438 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.20 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 6 |b 20 |c 06 |h 429-438 | ||